COVID-19 Convalescent Plasma Program
A world-renowned leader in infectious disease and transfusion medicine research, Vitalant Research Institute (VRI)—a division of Vitalant—is helping direct collection of blood plasma donations from recovered COVID-19 patients and developing technologies to detect and quantify virus-fighting antibodies. Recovered COVID-19 patients may have immune-boosting antibodies in their plasma; that plasma—called “convalescent plasma”—could be used to treat critically ill COVID-19 patients.
For customers who have a current agreement with Vitalant to receive CCP units:
CCP Product Label Examples
For customers recruiting potential CCP donors for qualification:
Donor Recruitment Flyer (English)
Donor Recruitment Flyer (Spanish)
Click to download a PDF flyer to help recruit potential CCP donors.
Donor Recruitment Email/Letter Template
Click to download a Word document with suggested email/letter copy to help recruit potential CCP donors.
Donor Recruitment Social Media Copy
Click to download a Word document with suggested social media copy to help recruit potential CCP donors.
Social media graphics
Click to download graphics you can post on social media with the suggested copy.
Frequently Asked Questions about Vitalant's Convalescent Plasma Program
How does a current, contracted hospital customer obtain convalescent plasma from Vitalant?
Once a contracted customer has worked with their local contact(s) and taken the necessary steps to be part of Vitalant’s convalescent plasma program, they will receive products from the donors they qualify and refer to Vitalant. Vitalant will notify the referring customer when the products are labeled/ready to distribute and will confirm the customer is ready to receive the units. Subsequent donations from the same donor go into general inventory and can be sent to any hospital with a convalescent plasma agreement. This increases every referring hospital’s likelihood of a needed unit being in inventory by allowing sharing across Vitalant’s network.
Vitalant is working to establish this general inventory of convalescent plasma.
How does a non-contracted hospital obtain convalescent plasma from Vitalant?
Non-contracted customers can reach out to Vitalant’s Inventory Management team at ProductManagement@vitalant.org
or to discuss potential convalescent plasma ordering.
What can your organization do now to prepare to accept convalescent plasma?
To prepare for program expansion and accepting convalescent plasma at your organization, please enter the following ISBT codes into your system as soon as possible.
|Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|COVID-19
|Apheresis CONVALESCENT PLASMA|ACD-A/XX/<= -18C|Irradiated|COVID-19
|Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19
|Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Psoralen-treated|COVID-19
We will communicate additional action items for organizations who wish to accept convalescent plasma as they are identified.
Where can your organization get the most up-to-date information about convalescent plasma?
This website is where we will maintain up-to-date information about the convalescent plasma program. We will continue to send email communications with major updates and required actions but please use this webpage as a frequently-checked resource at your organization.
If your organization is interested in the emergency use of investigational COVID-19 convalescent plasma, we strongly recommend you visit the FDA’s webpage regarding “Recommendations for Investigational COVID-19 Convalescent Plasma”
for more information about how your facility should work directly with the FDA to prepare.
Who should I contact at Vitalant about its convalescent plasma program?
If you represent a facility that has interest/need to transfuse active COVID-19 patients please reach out to your area’s Regional Account Manager and Medical Director
What types of investigational new drug (INDs) applications will Vitalant support?
Vitalant supports any IND your hospital uses to transfuse CCP: emergency INDs, in-house INDs, or the Mayo expanded access IND (Mayo EA IND). The FDA has determined that CCP is essentially a unique version of normal frozen plasma and thus the IND requirement falls on the treating hospital.
The FDA's website
contains excellent information for hospitals on how to get started with convalescent plasma, including how to establish a single patient eIND. All relevant forms and FDA contact information can be found on their website.
What is the Mayo process/expanded access IND (Mayo EA IND)?
The Mayo process/expanded access IND provides an alternative for hospitals to obtain FDA permission to transfuse convalescent plasma. All hospitals can be a part of the Mayo process – and must follow Mayo protocols.
More information can be found at: www.uscovidplasma.org
Can my institution set up its own process for transfusing convalescent plasma and not go through the Mayo process?
Yes. Because COVID-19 convalescent plasma has not yet been approved for use by FDA, it is regulated as an investigational product. As such, administration of COVID-19 convalescent plasma by a health care provider must be under an IND (a traditional institutional IND, the Mayo EA IND, or a single-patient emergency IND application).
Vitalant recommends contracted customers enroll in the Mayo program AND have a signed addendum in place with Vitalant to increase likelihood of getting critically needed products.
What is the Red Cross process for sourcing donors?
There are many avenues to identify and qualify potential donors including Vitalant’s website, the Red Cross and other providers’ websites, public health programs, and direct physician or hospital referrals. Donors who register with the Mayo program at www.uscovidplasma.org
may be referred to Red Cross’ website. If there is no local ARC center, the Red Cross will refer donors to their local blood center.
For questions regarding reimbursement for CCP products under various INDs/programs, please reach out to your Vitalant contact.